Skip to main content

Table 2 Guidelines for delay or discontinuation of IL-2 based on the number of assessed relative or absolute criteria

From: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response

Observation category Action
Any relative criteria - Initiate corrective measure +/− delayed IL-2;
Three criteria - Initiate corrective measure +/− delayed IL-2, stop IL-2 if not easily reversible;
Any absolute criteria - Initiate corrective measure +/− delayed IL-2, stop IL-2 if not easily reversible.